[EN]

Brussels - September 14, 2001Analysts and Investors Meeting

« A FUNDAMENTAL« A FUNDAMENTAL

STRATEGIC CHANGESTRATEGIC CHANGE

FOR SOLVAY »FOR SOLVAY »

PHARMACEUTICALSPHARMACEUTICALS

© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 2/08.092Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)

VALUE CREATING IN

PHARMACEUTICALS


SOLVAY PHARMACEUTICALSSOLVAY PHARMACEUTICALSOUR VISIONOUR VISION

““Our aim is to find, produce and deliver Our aim is to find, produce and deliver

pharmaceutical products to help pharmaceutical products to help

physicians to treat diseases physicians to treat diseases

in our 4 therapeutic areas and improve in our 4 therapeutic areas and improve

the quality of life for patients” the quality of life for patients”


SOLVAY PHARMACEUTICALSSOLVAY PHARMACEUTICALSmidsize company thrives by focusing on specialty areasmidsize company thrives by focusing on specialty areas

““The giants’ disdain for small drugsThe giants’ disdain for small drugscould work to the advantage ofcould work to the advantage of

midsize pharmaceutical companies”midsize pharmaceutical companies”McKinsey, 2001McKinsey, 2001


PHARMACEUTICALS SECTORPHARMACEUTICALS SECTORTargets by 2005+

Sales > EUR 2.5 Bn from 2005 onwardSales > EUR 2.5 Bn from 2005 onward

EBIT/sales margin > 15% EBIT/sales margin > 15%

ROI > 20%ROI > 20%

North American sales at 50% of total salesNorth American sales at 50% of total sales


PHARMACEUTICALS SECTORPHARMACEUTICALS SECTORTargets by 2005+

922

1548

2500

0

500

1000

1500

2000

2500

1996 2000 2005+

15%/y15%/y(+23% in US)(+23% in US)

World+ 10%/y required + 10%/y required

to achieve to achieve EUR 2.5 BnEUR 2.5 Bn


Growth of existing drugsGrowth of existing drugs Recent launch of new drugsRecent launch of new drugs Contribution of molecules under Contribution of molecules under

developmentdevelopment

PHARMACEUTICALS : FINANCIAL OBJECTIVE by 2005 sales of EUR 2.5 Bnsales of EUR 2.5 Bn EBIT/sales margin of 15%EBIT/sales margin of 15%

Strengthened by alliances and partnerships


« Expansion of global commercial platform »

J. Wessolowski, Head of Pharmaceuticals Marketing & Operations


PHARMACEUTICALS WORLDWIDE PRESENCEPHARMACEUTICALS WORLDWIDE PRESENCE

Total 2000 sales : EUR 1,548 M

Tokyo (Japan)

Brussels (B)Hannover (D)Weesp (NL)

Atlanta (USA)


STRONG WORLDWIDE MARKET POSITIONSTRONG WORLDWIDE MARKET POSITION

Europe US World Solvay (11)

WorldwideMarketShare

Digestives/Enzymes 1 2 1 33%Laxatives 1 - 3 6%Irritable Bowel Syndrome 1 - 1 28%Hormone Replacement Therapy

female 5 2 2 9%male (*) - 1 1 22%

Antidepressants + OCD 13 8 9 2%Vertigo (Ménière’s disease) 1 - 1 39%* only sold in the USIMS data


STRONG GROWTH IN 4 THERAPEUTIC AREASSTRONG GROWTH IN 4 THERAPEUTIC AREAS

HRT* PRODUCTS 470 + 21 % Estratest® 145+ 17% Duphaston® 56+ 7% Prometrium® 49+ 93% AndroGel® (**) 29n.a. Femoston® 19+ 60%

GASTROENTEROLOGY 473 + 11 % Creon® 119 + 6% Duphalac® 810 Duspatal® 59+ 2% Pantoloc® 54+ 101% Rowasa® 47+ 8% Dicetel® 34 + 9%

PSYCHIATRY 419 + 13 % Luvox® 271 + 19% Serc® 72 + 2%

CARDIOLOGY 106 + 6 % Physiotens® 39+ 26% Teveten® 16+ 20%

(*) Hormone Replacement Therapy (**) marketed since June 2000

Therapeutic fields/ Sales in 2000 2000/1999Products (M EUR) (%)


+ 19% SALES in H1/01 (+34% in the US)+ 19% SALES in H1/01 (+34% in the US)

HRT 267 + 46%

GASTRO 247 + 12%

CARDIO 73 + 47%

PSY 181 - 10%

H1/01 vs H1/00

• Estratest® 89 + 62%• AndroGel® 51 n.s.• Prometrium® 31 + 45%• (Cenestin (Duramed) 15 + 112%)

• Creon® 65 + 10%• Pantoloc® 37 + 65%• Rowasa® 27 + 29%• Dicetel® 20 + 21%

• Physiotens® 23 + 20%• Teveten® 17 + 157%• Aceon® 9 (*)

• Luvox® (world) 86 - 28% US down Japan up

• Marinol® 24 + 178%

Success of recently launched drugsSuccess of recently launched drugs

M EUR

H1/01H1/01M EUR M EUR vs H1/00vs H1/00

(*) Aceon® sales were negligible in H1/00


1999 2000 2001

Line extension: First launch of Femoston (conti.) in UK and Switzerland

Launch of Femoston (conti.) in Germany, further launches to follow

Poland, South Africa, Norway, Hungary, Sweden, Belgium, Russian Fed.

Lithuania, Croatia, Czech Rep., Slovak Rep., Malta, Bulgaria

Lebanon, Jordan, Saudi Arabia, Kuwait, U.A.E., Romania, Ukraine

First launch of Teveten (in Germany and US followed by further launches through the world

The Netherlands, Austria, UK, Ire, Switzerland, Australia, Poland, Italy, France, Russian Fed.

Fin, Gr, Canada, Sweden, Denmark, Norway, Spain, Belgium

First SSRI launched in Ja-pan; marketed by Fujisawa and Meiji Seika for depression and OCD

MAJOR RECENT PRODUCT LAUNCHES (1)MAJOR RECENT PRODUCT LAUNCHES (1)

Femoston®

Physiotens®

Teveten®

Luvox®


USA

Aceon ®

Androgel ®(marketing agreement with TAP

since June 2001)

Cenestin ®(with Duramed Inc.)

MAJOR RECENT PRODUCT LAUNCHES (2)MAJOR RECENT PRODUCT LAUNCHES (2)

2000 2001

Launch of Teveten

Marinol ®(100% Solvay)


2001 2003 2004 2005 2006

Teveten + HCT, Europe and U.S.

Presomen Conti,

(Germany only)

Moxonidine + HCT (Europe)

Luvox CR

Creon (Japan)

Estrogel US

cilansetron,Europe and U.S.

Tedisamil IV

CombigelE + P-gel

Influvac-Intranasal

SLV 306

DU 127090

Tedisamil PO

FUTURE PRODUCT LAUNCHESFUTURE PRODUCT LAUNCHES


GEOGRAPHICAL EXPANSIONGEOGRAPHICAL EXPANSION

76%

24%

60%

40%50% 50%

0%

10%

20%

30%

40%

50%

60%

70%

80%

ROW NAFTA1996

In %

of

tota

l p

har

ma

sale

s

2005+ROW = Rest of the World

targettarget : 50/50 balance between NAFTA / Rest of the world : 50/50 balance between NAFTA / Rest of the world

ROW NAFTA ROW NAFTA2000


GEOGRAPHIC GROWTH OBJECTIVESGEOGRAPHIC GROWTH OBJECTIVES

To increase global market share up to 0.8 - 1 % of the world market

(Market share currently 0.5%)

To get 1% in countries where Solvay has a presence


Countries in Billion USDSolvay

market share

* USA Market Estimates include audited US Mail Order data, **data for the Netherlands is based on estimated sales only (IMS data)

THE WORLDWIDE MARKETTHE WORLDWIDE MARKETRank

% of worldwidemarket

1 USA* 149.8 41.3% <1%2 Japan 57.8 15.9% <1%3 Germany 17.3 4.8% >1%4 France 16.8 4.6% >1%

6 Italy 11.0 3.0% <1%5 UK 11.1 3.0% <1%

10 Spain 6.2 1.7% >1%

8 Brazil 6.7 1.8% <1%7 China 6.8 1.9% <1%

9 Canada 6.3 1.7% <1%

11 Mexico 6.0 1.7% not present12 Argentina 3.7 1.0% not present13 South Korea 3.7 1.0% not present14 India 3.6 1.0% <1%15 Australia 3.1 0.9% <1%16 Turkey 3.1 0.9% not present

19 Belgium 2.5 0.7% >1%

17 Netherlands ** 2.6 0.7% <1%18 Poland 2.5 0.7% <1%

20 Taiwan 2.5 0.7% not present


ACQUISITIONS ACQUISITIONS NEW PRODUCTS/NEW COMPANIESNEW PRODUCTS/NEW COMPANIES

Recent/Short termRecent/Short term Medium term Medium term Long termLong term0 - 2 years0 - 2 years > 2 - < 5 years > 2 - < 5 years > 5 - years> 5 - years

USA Unimed X X

EUROPEItaly XUK XPoland (X)

+ Continuous growth Central/Eastern Europe, especially Russia+ geographical expansion in Turkey

AMERICASBrazil SintofarmaArgentina XMexico XCanada XASIAJapan X

+ geographical expansion in India


USAUSA Androgel®Androgel® :: with TAP Phamaceutical Cowith TAP Phamaceutical Co Cenestin®Cenestin® :: with Duramedwith Duramed Remeron® sol-tabRemeron® sol-tab :: with Organonwith Organon

CANADACANADA Pantoloc® Pantoloc® :: with Byk-Guldenwith Byk-Gulden Teveten ®Teveten ® :: with Fournierwith Fournier

SOUTH AMERICASOUTH AMERICA Mexico Mexico :: with Byk Guldenwith Byk Gulden ArgentinaArgentina :: with Byk Guldenwith Byk Gulden

EUROPEEUROPE GermanyGermany :: with Aventis for Teveten®with Aventis for Teveten® Spain Spain :: with Roche for Cilazapril®with Roche for Cilazapril® ItalyItaly :: with Upjohn for Frontal®with Upjohn for Frontal®

with Almirall/Prodesfarma for Dumirox® /Almotrex®with Almirall/Prodesfarma for Dumirox® /Almotrex®

ASIAASIA Japan Japan :: with Meiji and Fujisawa for Luvox®with Meiji and Fujisawa for Luvox® Japan Japan :: with Amano and with Meiji for Creon® with Amano and with Meiji for Creon® (under negotiation)(under negotiation) ChinaChina :: with Hexal (hostpartnership)with Hexal (hostpartnership)

ALLIANCES WITH SOUND PARTNERSALLIANCES WITH SOUND PARTNERSIN CO-PROMOTION/LICENSESIN CO-PROMOTION/LICENSES


EXPANSION OF COMMERCIAL SALES FORCEEXPANSION OF COMMERCIAL SALES FORCEAbout 5,300 sales representatives worldwide (versus 2,900 in 1998)

including sales force partners or third parties

SOLVAY SALES FORCE 3,800 United States 1,000 twofold increase between 98 and 2000

establishment of a primary care network acquisition of Unimed Pharmaceuticals Inc + alliance with Duramed (female HRT) and TAP (male

HRT, Androgel)) Brazil 180 Acquisition of Sintofarma in Brazil Canada 64 Western Europe 1,355 Central/Eastern Europe 300 Asia/Middle East 907

THIRD PARTIESJapan1,500 distribution agreement with Fujisawa/Meiji Seika


DOUBLE DIGIT GROWTHDOUBLE DIGIT GROWTH

96 97 98 99 00 H1/01

over the last 5 years

Sales 922 1,049 1,167 1,349 1,548 830

Sales Growth (yoy) +15% +14% +11% +16% +15% +19%

EBIT 97 118 135 157 134* 59

EBIT growth (yoy) +38% +22% +14% +16% -15%* +157%

EBIT/SALES 10% 11% 12% 12% 9%* 7%**

* due to voluntary marketing investments for the launch of 5 new drugs** with H1 lower than H2 due to seasonal effect


« Pharmaceuticals R&Dfor tomorrow ’s success »

W. Cautreels, Worldwide Head ofR&D Pharmaceuticals


Promising Development ProjectsPromising Development Projects an update by therapeutic area

But First An Update on Actions But First An Update on Actions Announced EarlierAnnounced Earlier

towards optimal decision making, output and effectiveness in R&D

strategic partnerships for biotech, special skills and value optimization

CONTENT OF PRESENTATIONCONTENT OF PRESENTATION


R&D EFFECTIVENESS IMPROVEMENTSR&D EFFECTIVENESS IMPROVEMENTS

handle the improved output from biotechnology based discovery programs:more compounds in development New biotech platform implemented New biotech platform implemented

accelerate the development process by working more effectively with expert Clinical Research Organisations as partners:reduce « time to market » Quintiles agreement implemented Quintiles agreement implemented

concentrate one function on one site:improve efficiency by avoiding duplications Implementation started Implementation started

shift internal R&D costs to external costs towards 50/50:increased portfolio development spending Implementation started Implementation started

(e.g. cilansetron)(e.g. cilansetron)

R&D EFFORTS BETTER FOCUSED (not reduced)R&D EFFORTS BETTER FOCUSED (not reduced)

Weesp Weesp (Nl),(Nl), Hannover Hannover (D),(D), Marietta and Chicago Marietta and Chicago (US),(US), Tokyo Tokyo (J)(J)


ProgramsProgramsDDProof ofPrincipleProof ofPrinciple ProjectsProjects LL ProductsProducts

Discovery and Biotech• for Compounds (Arqule +

Evotec + Syncom)• for Screening Technologies

(Euroscreen + Cerep)• for Targets (Innogenetics +

Euroscreen)

Development • in psychosis: Lundbeck• in HRT: several projects, E/P

gel with Antares• Lipase with Meristem• Intranasal influenza vaccine

with West

In preparation: preferred partner• for execution of clinical trials• with established quality global network• and state-of-the-art IT systems

QUINTILES

Business• Fujisawa/Meiji Seika (Jp)for

LUVOX & DEPROMEL• Byk-Gulden (D):

PANTOLOC in Canada• Several companies for

TEVETEN co-marketing• ANDROGEL co-marketing

with TAP in the US

Strategic Partnering makes us stronger!Strategic Partnering makes us stronger!some examples:some examples:


AREAS OF R&D FOCUSAREAS OF R&D FOCUS

Psychiatry Cardiology Gastroenterology

Anxiety &Depression

Psychosis

Parkinsons*

Arrhythmia

Congestive Heart Failure

Hypertension

Obesity*

MotilityDisorders

IrritableBowel Syndrome

PancreaticEnzymes

Hormone Replacements

Women HRT*

Endometriosis*

Men HRT*

* External collaborations


Hormone replacement therapies

17 %

Cardiology22 %

Psychiatry34 %

Gastroenterology27%

- in % of 2000 pharma R&D expenses : EUR 248 M(16% of pharma sales)

GROWTH THROUGH A SPECIALIZEDGROWTH THROUGH A SPECIALIZEDR&D PROGRAMR&D PROGRAM


R & D SUMMARY - NUMBER OF PROJECTSR & D SUMMARY - NUMBER OF PROJECTS

Gastro-Enterology

CNS HRT Cardiology

Pre-Clinical= 7

3(IBS (2), Enzyme

Insufficiency)

2(Parkinson’s,Psychosis)

2 (Hypertension/CHF)

Phase I= 3

3 (Psychosis)

Phase II= 8

2(Motility

Disorders, enzyme insufficiency)

4 (Parkinson’s,

Psychosis, Pain/Spasticity, Depression)

2 (arrhythmia,

Hypertension/CHF)

Phase III= 8

2(IBS, EnzymeInsufficiency)

1(OCD/Social

anxiety disorders)

3 (female HRT,

male HRT)

2(Hypertension)

Total=26 7 10 3 6

PSYCHIATRYPSYCHIATRYportfolioportfolio

SLV308

RegistrationProof ofprinciple

Research

LUVOX® fluvoxamine CR

DEPRESSION EU/JPNOCD US/EU/JPNOCD/Social Anxiety Disorders

SCHIZOPHRENIA/PSYCHOSIS

Multiple Sclerosis Pain/Spasticity

PARKINSON’S

SCHIZOPHRENIA PSYCHOSIS

DU127090

SLV310SLV313

SLV314DEPRESSIONDU125530

preclinical SLV318, SLV319

THC (MARINOL®)


PSYCHIATRYPSYCHIATRY

LUVOX® DEPRESSION EU/JPNOCD US/EU/JPNOCD/Social Anxiety Disorders

ELAN manufacture SOLVAY trademark (to be decided) positive pivotal studies in both OCD +

Social Anxiety Disorders submission 2002 US, 12 months delay

after validation of manufacturing

launch date 2003 onwards

peak sales potential under 100 MEUR

fluvoxamine CR


Research



cannabinoid receptor agonist, tetrahydrocannabinol (THC)

launched in US for appetite stimulation in HIV/AIDS and nausea/vomiting caused by cancer chemotherapy

clinical studies ongoing in relief of pain and spasticity in multiple sclerosis sufferers

Multiple Sclerosis pain/SpasticityTHC (MARINOL®)


Research



DU127090 Solvay Pharmaceuticals partnership with Lundbeck for joint

developments and marketing Partial D2 antagonist with additional 5HT1A agonism Proof of principle as antipsychotic is completed

SLV310/313/314 different mechanism mixes D2, 5HT1A, SSRI

SLV319 : a preclinical potential candidate

SCHIZOPHRENIA/ PSYCHOSIS

DU127090SLV310SLV313SLV314

Launch date 2006Peak sales potential

above 250 MEUR


Research


The Lundbeck Example of partnershipThe Lundbeck Example of partnership

We created DU 127090 and described its anti-psychotic potential by animal work and phase I clinical studies, phase II is ongoing

DU127090 shows promising anti-psychotic activity Lundbeck has very relevant skills with CNS project

and product experience Solvay and Lundbeck share costs, programs &

marketing (Solvay : US+other countries, Lundbeck : Europe)



SLV308 Partial D2 agonist plus 5HT1A agonism plus alpha-1 / alpha-2

agonism Parkinson’s first target + co-morbid depression Proof of principle studies on motor and mood disorders ongoing

Backup : SLV318 a preclinical potential candidate

PARKINSON’S SLV308


Research



Is a potent, full 5HT1A antagonist Atypical potential antidepressant Early clinical findings confirm antagonism in man with

opposite effects to buspirone, an agonist, on night time temperature and sleep

DEPRESSIONDU125530


Research


CARDIOLOGYCARDIOLOGYportfolioportfolio

CHF/ HYPERTENSION

ARRHYTHMIAS

TEVETEN®HCT

TEVETEN® EU / USACEON® US

PHYSIOTENS® EU HYPERTENSION

tedisamil IV-PO

preclinical SLV316, SLV320

moxonidine HCT

SLV306


Research


CARDIOLOGYCARDIOLOGY

HYPERTENSION

eprosartan plus hydrochlorotiazide (HCT) diuretic combinations

angiotensin II receptor antagonist to be marketed everywhere when registrations

and price agreementsachieved

“approvable letter” received from FDA

Launch date : 2001-2002Peak sales potential under

100 MEUR


Research


EFFICACY OF EPROSARTAN AND COMBINATIONS

eprosartan monotherapy works well for many hypertensive patients

eprosartan + HCT works well for some who need more than eprosartan alone

better response rate with eprosartan + HCT than with enalapril + HCT


CARDIOLOGY

moxonidine plus HCT diuretic combination

to be marketed in EU when registrations and price agreements achieved

moxonidine HCT

Launch date : 2003Peak sales potential under

100 MEUR


Research

HYPERTENSION


CARDIOLOGY

CHF/ HYPERTENSIONSLV306 Dual endopeptidase inhibitor NEP(1) and ECE(1)

hSEP is a novel ECE target (patent filed) selectively inhibited by SLV306 concept proven in both animals and man clinical proof of principle achieved for both

uses SLV306 is the front runner of this class development and marketing partnerships under

consideration(1) neutral endopeptidase (NEP) & endothelin converting enzyme (ECE)

Launch date : 2006Peak sales potential

above 250 MEUR


Research


CARDIOLOGY

ARRHYTHMIAS

potassium channel blocker intravenous use to convert atrial

fibrillation to sinus rhythm followed by oral use to maintain it

proof of principle achieved earliest launch 2004 intravenous and

2006 oral

tedisamil IV-PO

Launch date : 2004-2006Peak sales (IV+PO)

potential :100-250 MEUR


Research


GASTROENTEROLOGY portfolioportfolio

cilansetron US/EUDICITEL® EUCOLOFAC® EU IRRITABLE

BOWELSYNDROME

CREON® EU/USCREON® JPN

PANCREATICENZYMES

gastric lipase

MOTILITYDISORDERS

KC11458

preclinical SLV317, SLV321, enzymes


Research


GASTROENTEROLOGY

cilansetron US/EUDICITEL® EUCOLOFAC® EU IRRITABLE

BOWELSYNDROME

Cilansetron 5HT3 antagonist diarrhea-predominant IBS in men and women July 2001 decision to complete the phase III program Quintiles contract signed for clinical trials development and marketing commercial partnerships

now open for discussion


above 250 MEUR


Research


Start of the phase III program after constructive discussions with the US FDA

Agreement signed with QUINTILES TRANSNATIONAL access to state-of-the-art clinical trial execution with certain priority

claim on QUINTILES resources

ongoing talks with potential allianceand marketing partners

PROMISING and HIGH-POTENTIAL R&D PROJECTPROMISING and HIGH-POTENTIAL R&D PROJECTCILANSETRON FOR IBS IN PHASE IIICILANSETRON FOR IBS IN PHASE III


KEY DATA KEY DATA FROM CILANSETRON IBS STUDIESFROM CILANSETRON IBS STUDIES

2 large studies with similar results, 471 and

435 patients

cilansetron phase II pivotal studies show clear

separation from placebo both in men and

women, fall 2000


GASTROENTEROLOGY

CREON® EU/USCREON® JPN

PANCREATICENZYMES

CREON® JPN Launch date : 2003 Peak sales potential under 100 MEUR

gastric lipase non-animal-sourced range of enzymes sought “Molecular Pharming” technology expresses mammalian gastric-lipase in corn (MERISTEM) in-licensed for development, phase II ongoing

other non-animal-sourced enzyme products : preclinical

gastric lipase


Research


GASTROENTEROLOGY

MOTILITYDISORDERS

motilin agonist KC11458 is a non-peptide macrolide intended to be of use in the delayed gastric emptying found in some diabetic

gastroparesis patients and functional dyspepsias clinical studies show dose dependent effects in man confirming faster gastric

emptying phase II ongoing

KC11458


Research


HORMONE REPLACEMENTS portfolioportfolio

ESTROGEL® USPRESOMEN® EUFEMOSTON® EU

WOMEN’S HRT

ANDROGEL® US MEN’S HRT

ESTRATEST® US

E+P GEL US/EU


Research

Evaluation : testosterone for female use


HORMONE REPLACEMENTS

ESTROGEL® US

Launch date : 2003Peak sales potential under 100 MEUR


Research

New Drug Application submitted to FDA 1999

WOMEN’S HRT

HORMONE REPLACEMENTS

WOMEN’S HRTE+P GEL US/EU

Estradiol + NETA (progestogen) gel Solvay has obtained licenses for

US/Canada and Europe Clinical studies necessary to start

full-development have been completed

Phase III program to be started in Q1 2002


Research


under 100 MEUR


INFLUENZA VACCINES

INFLUVAC ® our current product was manufactured by Fort Dodge/AHP. We bought the factory mid 2001 in order to secure and expand manufacturing

WEST PHARMACEUTICALS intranasal formulation technology license obtained mid 2001 for use with our INFLUVAC ® launch expected 2005

MDCK process approved by Dutch authorities mid 2001, launch dates depend on future partnerships


2001 2003 2004 2005 2006

Teveten + HCT, Europe and U.S.< 100 MEUR

Moxonidine + HCT (Europe)<100 MEUR

Luvox CR<100MEUR

Creon (Japan)<100MEUR

Estrogel US<100MEUR

Cilansetron,Europe and U.S.

> 250MEUR

Tedisamil IV

CombigelE + P-gel

<100MEUR

Influvac-Intranasal<100MEUR

SLV 306>250MEUR

DU 127090>250MEUR

Tedisamil PO100-250MEUR

VALUATION OF R & D PORTFOLIOVALUATION OF R & D PORTFOLIOPeak sales Peak sales POTENTIAL POTENTIAL (3 years or more after launch)(3 years or more after launch)

This represents an all-success scenario, individual projects are subject to industry standard probabilities of success for their respective stage of development

LAUNCHLAUNCHDATESDATES


PHARMACEUTICALS R&D A Discovery with Proven Output AbilityA Discovery with Proven Output Ability

and a continuing search for external technologies and alliances

A Development with Proven Abilities to Proof Of PrincipleA Development with Proven Abilities to Proof Of Principle recent examples being cilansetron and SLV306

An Ability to Complete Full DevelopmentsAn Ability to Complete Full Developments recent examples being ESTROGEL® and fluvoxamine CR

And A Willingness to Work with Skilled PartnersAnd A Willingness to Work with Skilled Partners Lundbeck on DU127090 and Discussion ongoing for cilansetron, SLV306 and others

and … Innovation

Visit our Internet sitespecifically designed for Investors

www.solvay-investors.com

and become member of our Shareholders’ Club

[EN]

Documents

sales eur

sales of eur

aceon sales

total sales

estimated sales

luvox world

development pharmaceuticals

total pharma sales